AIT makes 162 million bid for Goldshield

Further to the announcement made on September 14, Israel's Fuhrer family-owned AIT and the independent directors have reached agreement on the terms of a recommended cash acquisition to be made for UK-based generic pharmaceutical and consumer health care company Goldshield, in deal valuing you latter at round £162.1 million ($263.6 million). It is intended that the deal will be implemented by way of a Court-sanctioned scheme of arrangement under Part 26 of the Companies Act.

The price of 440 pence in cash for each Scheme Share represents: a premium of approximately 36% to the 323.5 pence per Goldshield share at June 23, the day before the announcement by Goldshield that it had received approaches concerning a possible offer; a 35.9% premium for the three-month period ending that date and 53% more than that prior to the original announcement. .